pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
Drugs
by stage
Marketed
Phase 3
Phase 2
Phase 1
Preclinical
browse
Most catalysts
Recently active
All drugs →
Companies
Patent cliff
Calendar
what
Trial readouts
PDUFA dates
Approvals
Earnings
when
Upcoming
Month grid
Recently passed
◐
Sign In
Subscribe
home
jobs
news
search
Monoclonal Antibody · news · pharmadog
← back to Monoclonal Antibody
News · Monoclonal Antibody
785
stories
22d
Genmab soars to record highs after cancer drug succeeds in key trial
biopharma dive
22d
Merck looks ahead to ‘another year of investment’ as Keytruda cliff looms
biospace
22d
BMS drops Prothena-partnered neuro drug, sales outlook improves on a Q3 beat
biospace
22d
Genmab's stock rises on cancer data, while Iovance, Coherus tumble
endpoints
23d
Merck outlines 2027 as ‘another year of investment’ despite recent clinical wins
fiercebiotech
23d
BMS walks away from $80M neurodegeneration bet after phase 1
fiercebiotech
23d
8 companies hiring in New York
biospace
23d
Genmab’s cancer bispecific delivers early survival win in ‘exceedingly positive’ Phase 3 readout
biospace
23d
Genmab’s cancer bispecific delivers early OS win in ‘exceedingly positive’ Phase 3 readout
biospace
23d
Biogen set up for growth even without M&A but CEO won’t rule it out
biospace
23d
GSK vaccine sales miss expectations amid falling demand from adults
biospace
23d
Lilly shuffles business structure; Novartis writes off part of Avidity deal
biopharma dive
23d
Astellas bets up to $1.34B for option to advance Audax immuno-oncology asset
biospace
23d
Genmab's $8B Merus bet delivers as bispecific combo halves risk of death in phase 3
fiercebiotech
24d
Data leak kickstarts ESMO, BMS reports autoimmune CAR T death, pharma M&A outpaces 2025
biospace
24d
Biogen CEO tells analysts he’s focused on early-stage R&D as ‘we were not very good with that’
fiercebiotech
24d
GSK predicts ‘some limited impact’ to UK roles as restructuring rolls on
fiercebiotech
24d
Astellas makes $1.3B bet on Audax’s preclinical push to reverse decades of IL-12 woes
fiercebiotech
24d
Outpace ends an ovarian cancer trial; Incyte data impresses at ESMO
endpoints
24d
Novartis faces $1.9B hit from Avidity fail but maintains confidence in $12B buy
biospace
24d
A possible treatment for brain-eating amoebas, found in the sea
stat
25d
Parkinson’s-focused Aspen and bispecific biotech Bambusa both shoot for $134M IPOs
fiercebiotech
25d
From RAS rivalries to leaked cancer vaccine readouts, ESMO brought the data drama
fiercebiotech
25d
Novartis CEO keeps faith in Avidity deal despite taking $1.9B hit from del-desiran fail
fiercebiotech
25d
GSK’s B7-H3 ADC drives 67% cancer risk reduction in Hansoh's phase 3 China trial
fiercebiotech
25d
BioNTech, DualityBio say ADC had ‘modest’ benefit in breast cancer study
biopharma dive
25d
ESMO 2026: Merck’s Kelun-partnered ADC cuts death risk by over 30% in endometrial cancer
biospace
25d
STAT+: Merck ADC drug cut risk of death by one-third in advanced endometrial cancer
stat
25d
Aspen, Bambusa target $135M IPOs; AstraZeneca vs. Takeda in gastric cancer ADCs
endpoints
25d
ESMO 2026: Analysts warm to Merck, Moderna’s cancer vaccine after frustrating data leak
biospace
← prev
page 5 of 27
next →